Expression of myr-Akt was sufficient to induce by 6–8 weeks an MPD and a T-cell lymphoma with high frequency (90% and 65%, respectively), and an AML with a lower penetrance (10%, without any evidence of preexisting MPD). The gene discussed is AKT1; the disease is T-cell non-Hodgkin lymphoma.